TY  - GEN
AU  - Raizer,J J
AU  - Giglio,P
AU  - Hu,J
AU  - Groves,M
AU  - Merrell,R
AU  - Conrad,C
AU  - Phuphanich,S
AU  - Puduvalli,V K
AU  - Loghin,M
AU  - Paleologos,N
AU  - Yuan,Y
AU  - Liu,D
AU  - Rademaker,A
AU  - Yung,W K
AU  - Vaillant,B
AU  - Rudnick,J
AU  - Chamberlain,M
AU  - Vick,N
AU  - Grimm,S
AU  - Tremont-Lukats,I W
AU  - De Groot,J
AU  - Aldape,K
AU  - Gilbert,M R
TI  - A phase II study of bevacizumab and erlotinib after radiation  and temozolomide in MGMT unmethylated GBM patients
SN  - 1573-7373
PY  - 2016///0928
KW  - Adult
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Bevacizumab
KW  - Brain Neoplasms
KW  - drug therapy
KW  - DNA Methylation
KW  - DNA Modification Methylases
KW  - genetics
KW  - Dacarbazine
KW  - adverse effects
KW  - Disease-Free Survival
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Glioblastoma
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Prognosis
KW  - Radiotherapy
KW  - Temozolomide
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s11060-015-1958-z
ER  -